Cabaletta Bio, Inc. (CABA) AI Dilution Summary

Estimated cash was $311,274,796 as of 2026-09-12, rolled forward from $225,101,000 at 2026-06-30, against estimated monthly burn of $14,012,500. The funding channel in use is the ATM program with TD Securities (USA) LLC (TD Cowen), authorised to $150,000,000. It has sold 16,095,313 shares since the program began, through 2026-08-13; sales after 2026-08-13 are not yet reported.